Search results

  1. Barrett's oesophagus

    Everything NICE has said on treating adults with Barrett's oesophagus who have high-grade dysplasia or early intramucosal cancer in an interactive flowchart

  2. Colorectal cancer

    Everything NICE has said on diagnosing and managing colorectal (bowel) cancer in an interactive flowchart

  3. Oesophageal and gastric cancer

    Everything NICE has said on assessing and managing non-stromal oesophageal and gastric cancer in adults

  4. Ovarian cancer

    Everything NICE has said on recognising and managing ovarian cancer in an interactive flowchart

  5. Urogenital conditions

    Everything NICE has said on urogenital conditions in an interactive flowchart

  6. Gastrointestinal conditions

    Everything NICE has said on gastrointestinal conditions in an interactive flowchart

  7. Eczema

    Everything NICE has said on managing atopic eczema in children up to 12 years, and treating eczema in people aged 13 years and over in an interactive flowchart

  8. Further research is recommended to assess the diagnostic yield of the BioMonitor 2‑AF and Confirm Rx (or later devices) for atrial fibrillation when used in people who have had a cryptogenic stroke. The committee noted that existing ongoing research may provide further data for these devices (see  section 3.51   and  section 4.19 ).

    Recommendation ID DG41/1 Question Further research is recommended to assess the diagnostic yield of the BioMonitor 2‑AF and Confirm Rx

  9. NICE encourages further research into implanted vagus nerve stimulation for treatment-resistant depression, in the form of randomised controlled trials with a placebo or sham stimulation arm. Studies should report details of patient selection. Outcomes should include validated depression rating scales, patient-reported quality of life, time to onset of effect and duration of effect, and any changes in concurrent treatments.

    Recommendation ID IPG679/1 Question NICE encourages further research into implanted vagus nerve stimulation for treatment-resistant depression

  10. SEM Scanner 200, with visual skin assessment, shows promise for preventing pressure ulcers. However, there is not enough good-quality evidence to support the case for routine adoption in the NHS. A randomised controlled trial is recommended to address uncertainties about the clinical benefits of using the scanner compared with standard risk assessment. This should assess: using the scanner plus visual skin assessment compared with visual skin assessment alone for identifying pressure ulcer risk whether changes in clinical decision making from using the scanner reduce pressure ulcer incidence the clinical benefits and resource impact of using the scanner in different care settings the clinical benefits for different skin tones how well the scanner works across populations with a range of comorbidities patient-related outcome measures.

    Recommendation ID MTG51/1 Question SEM Scanner 200, with visual skin assessment, shows promise for preventing pressure ulcers. However